CSL Limited Stock OTC Markets

Equities

CSLLY

US12637N2045

Pharmaceuticals

Market Closed - OTC Markets 15:56:04 2024-05-24 EDT 5-day change 1st Jan Change
93.47 USD +1.13% Intraday chart for CSL Limited -0.57% -3.81%
Sales 2024 * 14.72B 20.1B Sales 2025 * 15.93B 21.76B Capitalization 90.02B 123B
Net income 2024 * 2.71B 3.7B Net income 2025 * 3.26B 4.45B EV / Sales 2024 * 6.78 x
Net Debt 2024 * 9.82B 13.41B Net Debt 2025 * 8.65B 11.82B EV / Sales 2025 * 6.19 x
P/E ratio 2024 *
32.9 x
P/E ratio 2025 *
27.4 x
Employees 32,065
Yield 2024 *
1.42%
Yield 2025 *
1.66%
Free-Float 99.53%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.13%
1 week-0.57%
Current month+4.32%
1 month+3.67%
3 months-0.32%
6 months+9.58%
Current year-3.81%
More quotes
1 week
91.33
Extreme 91.33
94.40
1 month
88.70
Extreme 88.7
96.09
Current year
85.96
Extreme 85.96
99.54
1 year
71.51
Extreme 71.51
105.11
3 years
71.51
Extreme 71.51
117.49
5 years
69.98
Extreme 69.98
117.98
10 years
29.60
Extreme 29.6
117.98
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 19-05-31
Director of Finance/CFO 59 20-09-30
Chief Tech/Sci/R&D Officer 62 20-09-30
Members of the board TitleAgeSince
Director/Board Member 69 19-12-08
President 68 90-06-30
Director/Board Member 61 21-08-18
More insiders
Date Price Change Volume
24-05-24 93.47 +1.13% 30,624
24-05-23 92.43 +0.87% 33,023
24-05-22 91.63 -0.95% 50,743
24-05-21 92.51 -0.25% 18,227
24-05-20 92.74 -1.35% 48,789

Delayed Quote OTC Markets, May 24, 2024 at 03:56 pm

More quotes
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
186.3 USD
Average target price
202.7 USD
Spread / Average Target
+8.80%
Consensus